Reports and Briefs on Oncology

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

Type Product title / description Pub Price
Report
Report

Myelodysplastic Syndrome: An Underserved Population Offers Commercial Opportunity

SuperGen/MGI Pharma's Dacogen and Celgene's Revlimid are in pre-registration for treatment of myelodysplastic syndrome (MDS). However, a significant proportion of the MDS population will be left underserved by pharmacotherapy.

Published By Datamonitor
18 Oct 2005 $1900
Buy
Report
Report

Pipeline Insight: Prostate Cancer - Molecular targeted therapies will fulfill unmet needs in castration-resistant disease

Overview of the current prostate cancer clinical pipeline, including in-depth analysis of late-phase products, clinical trial data, sales forecasts through to 2018, Datamonitor drug assessment summaries and key opinion leader insight.

Published By Datamonitor
14 Aug 2009 $11400
Buy
Report
Report

Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy

Primary research-based analysis of the chronic leukemias market. Includes patient segmentation, treatment trends, prescribing influences and brand perception.

Published By Datamonitor
08 Oct 2009 $15200
Buy
Report
Report

Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine

Overview of the current colorectal cancer clinical pipeline, including in-depth analysis of late-phase products, clinical trial data, sales forecasts through to 2018, Datamonitor drug assessment summaries and key opinion leader insight.

Published By Datamonitor
21 Oct 2009 $11400
Buy
Report
Report

Stakeholder Opinions: Gene Therapy - Gene therapy to deliver after 20 years of clinical development

Comprehensive analysis of the gene therapy clinical pipeline across all geographic and therapeutic markets, with key opinion leader insights. Identification of drivers and inhibitors to the commercial success of gene therapy.

Published By Datamonitor
10 Dec 2009 $3800
Buy
Report
Report

Stakeholder Insight: Non-Hodgkin's Lymphomas Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)

Primary research-based analysis of the non-Hodgkin's lymphomas market, including epidemiology, patient segmentation, and treatment data. Separate coverage of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Published By Datamonitor
17 Dec 2009 $15200
Buy
Report
Report

Stakeholder Insight: Cancer Pain - Physician survey highlights inadequacies in education and treatment

Datamonitor surveyed 180 oncologists, anesthetists, palliative medicine specialists and pain care specialists in the seven major markets to gain insight into cancer pain prevalence, treatment trends and key prescribing influences.

Published By Datamonitor
23 Dec 2009 $15200
Buy
Report
Report

Pipeline Insight: Biologic Targeted Cancer Therapies - Next generation jostles for market position

Overview of the current biologic molecular targeted therapies pipeline in oncology, including analysis of late-phase products, clinical trial data, sales forecasts through to 2018, Datamonitor drug assessment summaries and key opinion leader insight.

Published By Datamonitor
24 Dec 2009 $11400
Buy
Report
Report

Stakeholder Opinions: Cervical and Endometrial Cancer - Opportunities remain outside the big gynecologic malignancies

Key issues in the gynecological malignancies market, focusing mainly on endometrial and cervical cancer, including forecast epidemiology, current treatment trends and controversies, unmet needs, insight into pipeline activity and stakeholder opinion.

Published By Datamonitor
17 Mar 2010 $3800
Buy
Report
Report

Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic gastrointestinal cancers represent a significant commercial opportunity due to a lack of approved drugs

Overview of the current gastrointestinal cancers clinical pipeline, including in-depth analysis of late-phase products, clinical trial data, sales forecasts through to 2019, Datamonitor drug assessment summaries and key opinion leader insight.

Published By Datamonitor
25 Mar 2010 $11400
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

No help is available.